Financings In Brief
This article was originally published in The Gray Sheet
TherOx raises $30 million: Privately held developer of the DownStream SuperSaturated Oxygen Therapy system for adjunctive treatment of acute myocardial infarction raises $30 million from DAG Ventures and other investors. A PMA application for the device is pending. Downstream is designed to reduce infarct size and preserve heart muscle after a severe heart attack by super oxygenating a patient's blood for direct re-infusion to oxygen deficient tissue after a patient has already been treated with balloon angioplasty and a stent. Based in Irvine, Calif., the firm reported results last October from its pivotal, 300-patient AMIHOT II trial, including a statistically significant 6.5% reduction in infarct size using the device. Other potential applications for the technology include ischemic stroke, cancer and wound healing, according to the company (1"The Gray Sheet" Dec. 3, 2007, p. 15)
You may also be interested in...
Four manufacturers are seeking new-technology payments for their devices in the fiscal year 2009 inpatient payment rule, despite industry's frustration with CMS' process for granting the add-on payments
GSK launches a 100% natural saline spray in the UK to compliment its Piri hayfever brand portfolio.
Progress for two US-based companies in the race to develop a COVID-19 vaccine.